China Approves AstraZeneca's Tagrisso (Osimertinib) With The Addition Of Pemetrexed And Platinum-based Chemotherapy For The First-Line Treatment Of Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
China Approves AstraZeneca's Tagrisso (Osimertinib) With The Addition Of Pemetrexed And Platinum-based Chemotherapy For The First-Line Treatment Of Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
中國批准阿斯利康的Tagrisso（奧西替尼）配合培美曲塞和鉑類化療用於局部晚期或轉移性EGFR突變非小細胞肺癌的一線治療。
China Approves AstraZeneca's Tagrisso (Osimertinib) With The Addition Of Pemetrexed And Platinum-based Chemotherapy For The First-Line Treatment Of Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
中國批准阿斯利康的Tagrisso（奧西替尼）配合培美曲塞和鉑類化療用於局部晚期或轉移性EGFR突變非小細胞肺癌的一線治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。